Acorda Therapeutics (ACOR) Gets a Hold Rating from J.P. Morgan
J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Acorda Therapeutics (NASDAQ: ACOR) today. The company’s shares opened today at $17.75, close to its 52-week low of $15.60.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 1.4% and a 38.3% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Jounce Therapeutics Inc, and Editas Medicine Inc.
Acorda Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $24.50, a 38.0% upside from current levels. In a report issued on October 5, Stifel Nicolaus also maintained a Hold rating on the stock with a $19 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.35 and a one-year low of $15.60. Currently, Acorda Therapeutics has an average volume of 692.3K.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules.
Read More on ACOR: